Candida antigen vaccine

Phase 2Vaccine

ZZagazig University

Candida antigen vaccine is one of 4 biologic programs targeting HPV Vaccine. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HPV VaccineRecruiting

HPV VaccinePhase 2

Recruiting

Competition

Competitive Landscape

4 competitors in HPV Vaccine

#DrugCompanyPhaseTrials

HPV Vaccine

SShanghai Zerun Biotechnology Co.,Ltd

Phase 3

1 2

Nonavalent HPV Vaccine

XXiamen University

Phase 3

1 3

Bivalent HPV Vaccine

ZZagazig University

Phase 2

1 4

Candida antigen vaccine

ZZagazig University

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

HPV Vaccine1 trial

Candida Antigen and Bivalent HPV Vaccine in the Treatment of Multiple Warts

Recruiting·ZZagazig University·Phase 2·NCT05291845·162 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Candida antigen vaccine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Candida antigen vaccine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Candida antigen vaccine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Zagazig University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Vaccine[2]
Highest Phase: Phase 2[1]
Company: ZZagazig University

Candida antigen vaccine

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

HPV Vaccine1 trial

References

Drug Info

Quick Facts

Related News